Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials

被引:0
作者
Chitkara, Akshit [1 ,5 ]
Sreenivasan, Sushanth [2 ]
Yin, Yue [3 ]
Rai, Maitreyee [4 ]
Sadashiv, Santhosh [4 ]
机构
[1] Univ Calif Riverside, Dept Internal Med, Riverside, CA 92521 USA
[2] Allegheny Hlth Consortium, Dept Internal Med, Pittsburgh, PA 15222 USA
[3] Allegheny Singer Res Inst, Pittsburgh, PA 15212 USA
[4] Allegheny Hlth Network Canc Inst, Div Hematol & Cellular Therapy, Pittsburgh, PA 15224 USA
[5] Thomas Jefferson Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Hematol Oncol, Philadelphia, PA 19107 USA
关键词
Chimeric Antigen Receptor T-cell (CAR-T); venous thromboembolism; meta-analysis; hematological malignancies; mantle cell lymphoma; B-cell lymphoma; multiple myeloma;
D O I
10.3390/curroncol31080323
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chimeric Antigen Receptor T-cell (CAR-T) therapy uses genetically engineered T-cells with specific binding sites. This therapy allows for tumor specificity and durable treatment responses for patients with hematological malignancies. In this review, we study the risk of venous thromboembolism (VTE) associated with CAR-T therapy. We searched the National Institutes of Health library, Cochrane Library Databases, ClinicalTrials.gov database, and medical literature search engines PubMed and Google Scholar for Phase 2 and Phase 3 drug-efficacy and safety trials to determine the aggregate incidence and risk of VTE treated with CAR-T. Of 1127 search results, nine studies were identified and included in our meta-analysis. Of the 1017 patients who received therapy, 805 patients (79.15%) experienced some degree of CRS, and 122 patients (11.9%) experienced severe CRS (higher than grade 3). Only three out of one thousand and seventeen patients were reported to have experienced venous thromboembolism. Our study did not find a statistically significant association between increased VTE incidence (OR = 0.0005, 95% CI [0.0001, 0.0017]) and CRS/ICANS (p < 0.0001). There was a 0.0050 (95% confidence interval [0.0019, 0.0132]) relative risk for VTE. In our study, we did not find a statistically significantly increased risk of developing VTE despite CRS and underlying malignancy, which have been associated with increased risk of VTE.
引用
收藏
页码:4338 / 4345
页数:8
相关论文
共 20 条
  • [1] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Z.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam D.
    Stewart, A. Keith
    Hari, Parameswaran
    Htut, Myo
    Lesokhin, Alexander
    Deol, Abhinav
    Munshi, Nikhil C.
    O'Donnell, Elizabeth
    Avigan, David
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Deraedt, William
    Zhuang, Sen Hong
    Infante, Jeffrey
    Geng, Dong
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Rizvi, Syed
    Fan, Frank
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    [J]. LANCET, 2021, 398 (10297) : 314 - 324
  • [2] A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy
    Bindal, Poorva
    Patell, Rushad
    Chiasakul, Thita
    Lauw, Mandy N.
    Ko, Amica
    Wang, Tzu-Fei
    Zwicker, Jeffrey I.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (07) : 2071 - 2080
  • [3] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
    Bishop, M. R.
    Dickinson, M.
    Purtill, D.
    Barba, P.
    Santoro, A.
    Hamad, N.
    Kato, K.
    Sureda, A.
    Greil, R.
    Thieblemont, C.
    Morschhauser, F.
    Janz, M.
    Flinn, I
    Rabitsch, W.
    Kwong, Y-L
    Kersten, M. J.
    Minnema, M. C.
    Holte, H.
    Chan, E. H. L.
    Martinez-Lopez, J.
    Mueller, A. M. S.
    Maziarz, R. T.
    McGuirk, J. P.
    Bachy, E.
    Le Gouill, S.
    Dreyling, M.
    Harigae, H.
    Bond, D.
    Andreadis, C.
    McSweeney, P.
    Kharfan-Dabaja, M.
    Newsome, S.
    Degtyarev, E.
    Awasthi, R.
    del Corral, C.
    Andreola, G.
    Masood, A.
    Schuster, S. J.
    Jaeger, U.
    Borchmann, P.
    Westin, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) : 629 - 639
  • [4] The Role of Inflammation in Venous Thromboembolism
    Branchford, Brian R.
    Carpenter, Shannon L.
    [J]. FRONTIERS IN PEDIATRICS, 2018, 6
  • [5] CAR-T: What Is Next?
    Chen, Yi-Ju
    Abila, Bams
    Mostafa Kamel, Yasser
    [J]. CANCERS, 2023, 15 (03)
  • [6] A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation
    Doyle, Andrew J.
    Hunt, Beverley J.
    Sanderson, Barnaby
    Zhang, Joseph
    Mak, Sze M.
    Benedetti, Guilia
    Breen, Karen A.
    Camporota, Luigi
    Barrett, Nicholas A.
    Retter, Andrew
    [J]. CRITICAL CARE MEDICINE, 2021, 49 (07) : E663 - E672
  • [7] Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
    Hashmi, Hamza
    Mirza, Abu-Sayeef
    Darwin, Alicia
    Logothetis, Constantine
    Garcia, Franco
    Kommalapati, Anuhya
    Mhaskar, Rahul S.
    Bachmeier, Christina
    Chavez, Julio C.
    Shah, Bijal
    Pinilla-Ibarz, Javier
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien
    Davila, Marco L.
    Locke, Frederick L.
    Nishihori, Taiga
    Jain, Michael D.
    [J]. BLOOD ADVANCES, 2020, 4 (17) : 4086 - 4090
  • [8] Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
    Jacobson, Caron A.
    Chavez, Julio C.
    Sehgal, Alison R.
    William, Basem M.
    Munoz, Javier
    Salles, Gilles
    Munshi, Pashna N.
    Casulo, Carla
    Maloney, David G.
    de Vos, Sven
    Reshef, Ran
    Leslie, Lori A.
    Yakoub-Agha, Ibrahim
    Oluwole, Olalekan O.
    Fung, Henry Chi Hang
    Rosenblatt, Joseph
    Rossi, John M.
    Goyal, Lovely
    Plaks, Vicki
    Yang, Yin
    Vezan, Remus
    Avanzi, Mauro P.
    Neelapu, Sattva S.
    [J]. LANCET ONCOLOGY, 2022, 23 (01) : 91 - 103
  • [9] Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
    Johnsrud, Andrew
    Craig, Juliana
    Baird, John
    Spiegel, Jay
    Muffly, Lori
    Zehnder, James
    Tamaresis, John
    Negrin, Robert
    Johnston, Laura
    Arai, Sally
    Shizuru, Judith
    Lowsky, Robert
    Meyer, Everett
    Weng, Wen-Kai
    Shiraz, Parveen
    Rezvani, Andrew
    Latchford, Theresa
    Mackall, Crystal
    Miklos, David
    Frank, Matthew
    Sidana, Surbhi
    [J]. BLOOD ADVANCES, 2021, 5 (21) : 4465 - 4475
  • [10] Chimeric Antigen Receptor Therapy
    June, Carl H.
    Sadelain, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 64 - 73